In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Medical Services Patients & Visitors Health Library For Medical Professionals Quality About Us PhysicianLink
Text Size:  -   +  |  Print Page  |  Email Page

Breast Cancer



A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER-2 Positive Ductal Carcinoma In Situ (DCIS) Resected by Lumpectomy. 

For additional information please contact Nurdan IIgaz, Clinical Research Coordinator, at 859-260-6406. 
REF# CBG 09-870

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Follower by Weekly Paclitaxel) to Chemotherapy plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.

For additional information please contact Nurdan IIgaz, Clinical Research Coordinator, at 859-260-6406.
REF# CBH 11-953

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy In Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. 

For additional information please contact Heather Tudor, Clinical Research Coordinator, at 859-260-3196.
REF# CBH 11-979

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer.

For additional information please contact Heather Tudor, Clinical Research Coordinator, at 859-260-3196.
REF# CBH-13-1084

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA).

 

For additional information please contact Heather Tudor, Clinical Research Coordinator, at 859-260-3196. 
REF# BHL-13-1096

 

Phase II Study of Neoadjuvant Letrozole for Post-Menopausal Women with Estrogen Receptor Positive Ductal Carcinoma In Situ.

 

For additional information please contact Nurdan Ilgaz, Clinical Research Coordinator, at 859-260-6406. 
REF# BHL-13-1101

 

A Cot Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (horAIMSS).

For additional information please contact Heather Tudor, Clinical Research Coordinator, at   859-260-3196.  REF# BHL-13-1139

A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer. 

For additional information please contact Heather Tudor, Clinical Research Coordinator, at 859-260-3196.  REF# BHL-13-1146

Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention with Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim

For additional information please contact Heather Tudor, Clinical Research Coordinator, at 859-260-3196. 
REF# BHL-13-1138

ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study

For additional information please contact Heather Tudor, Clinical Research Coordinator, at 859-260-3196.  REF# BHL-14-1151

A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of  Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation

For additional information please contact Nurdan Ilgaz, Clinical Research Coordinator, at 859-260-6406.    REF# BHL-13-1164

 

Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer

For additional information please contact Nurdan Ilgaz, Clinical Research Coordinator, at 859-260-6406. 
REF# BHL-13-1170

 Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole:  A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients with Hormone-Receptor Positive Stage IV Breast Cancer

For additional information please contact Heather Tudor, Clinical Research Coordinator, at 859-260-3196. 
REF# BHL-13-1101